Safe Shipping to UK, USA, Sweden Semaglutide CAS 910463-68-2

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >99%
• Model NO.: HHD
• CAS: 910463-68-2
• Mf: C187h291n45o59
• COA: Available
• Shelf Life: 2 Years
• Transport Package: Bag
• Specification: Customized
• Trademark: HHD
• Origin: Hubei
• Production Capacity: 50000 Pieces Per Year

Product Description

 

Wuhan hhd 99% High Quality Peptides Semaglutide CAS 910463-68-2

Description

 

CAS NO:	910463-68-2
Product Name:	Semaglutide
Synonyms:	Sermaglutide;Semaglutide fandachem;Semaglutide impurity;Sermaglutide USP/EP/BP;semaglutide;Sermaglutide CAS 910463 68 2
Molecular Formula:	C187H291N45O59
Formula Weight:	4113.57754
Appearance:	Solid powder
Purity:	>98%
Storage:	Dry, dark, and at 0 - 4 C for the short term (days to weeks) or -20 C for the long term (months to years).
Solubility:	Soluble in DMSO
Shipping Condition:	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

 

 

Prodcut name	Semaglutide
Standard packing material	Aluminum foil bag inside, then waterproof bag or carton
Appearance	White powder
Purity	99%
Storage	Lyophilized peptides although stable at room temperature for 3 months, should be stored  desiccatedbelow -18° C. Upon reconstitution of the peptide it should be stored at 4° C between 2-21 days and for future use below -18° C.

      Semaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, which is more effective in treating type 2 diabetes.Semaglutide This trial investigated the efficacy and safety of 1.0 mg of semaglutide compared with 2.0 mg of exenatide once weekly in 813 patients with type 2 diabetes for a period of 56 weeks. Oral 1-2 antidiabetic drugs at the same time. In December 2017, the FDA officially approved the once-a-week GLP-1 hypoglycemic drug semaglutide, a once-a-week GLP-1 hypoglycemic drug developed by Novo Nordisk, under the trade name Ozempc. According to clinical trial data, Ozempc can reduce HbA1c levels compared to placebo, Merck's Januvia, AstraZeneca's Bydureon and Sanofi's Lantus. The drug has also shown the ability to help patients lose weight
 

GLP-1 agonists were approved by the FDA for weight loss in late 2014. It's a newer class of drugs better known for its ability to improve blood sugar control. These medications were actually designed to treat type II diabetes, but some have also been FDA approved to treat weight loss. The GLP-1 agonists we work with are called Semaglutide & Tirzepatide. Semaglutide is also known Ozempc or Wegvy. Tirzepatide is known as Mounjao.

Tirzepatide is dosed at 5-15mg per week

Semaglutide is dosed at 0.5-2.4mg per week

BENEFITS OF GLP-1 AGONISTS

•  
• Helps slow food leaving your stomach
• Helps prevent your liver from making too much sugar
• Helps the pancreas produce more insul when your blood sugar levels are high
• Can help control blood glucose
• Can reduce hyperglycemia, especially after meals
• Can reduce fasting insul and fasting glucose
• Can reduce hemoglobin A1c
• Can decrease appetite and caloric intake, while inhibiting weight gain
• Has been shown to lower triglyceride levels and oxidative stress from high LDL
• Has been shown to help induce weight loss in obese patients with higher dosing
• Helps decrease leptin and increase leptin sensitivity
• Can increase the conversion of white fat to brown fat
•  Tirzepatide Product Information 
• Product Name :Tirzepatide
• Trade Name: HHD Pharm
  CAS No.:2023788-19-2
  Purity : 98% HPLC
  Appearance:  Lyophilized Powder
  Typical use: weight loss peptides
  Shelf Life :2 years
  Storage:Refrigeration keep dry and away from light.
  
  Description:
  
  Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under development for the treatment of type 2 diabetes (T2D) and obesity. 
  
  Tirzepatide is a dual glucose-dependent insulinotropic polypeptide-GLP-1 receptor agonist. Its structure is primarily based on the glucose-dependent insulinotropic polypeptide amino acid sequence and includes a C20 fatty diacid moiety. Its half-life of approximately 5 days allows once-weekly subcutaneous administration. A phase 2b trial involving patients with type 2 diabetes showed that those who received tirzepatide had dose-dependent reductions in the glycated hemoglobin level and weight at 26 weeks.
  Once-weekly injectable semaglutide, a selective GLP-1 receptor agonist, is approved for the treatment of type 2 diabetes at doses up to 1 mg. In trials involving patients who received semaglutide, the mean reductions in the glycated hemoglobin level have been reported to be as high as 1.8 percentage points and the mean reductions in body weight have been reported to be as high as 6.5 kg.
  We conducted the SURPASS-2 trial (A Study of Tirzepatide [LY3298176] versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants with Type 2 Diabetes) to compare the efficacy and safety of tirzepatide at doses of 5 mg, 10 mg, and 15 mg with those of semaglutide at a dose of 1 mg in patients with type 2 diabetes that had been inadequately controlled with metformin monotherapy.
  
  
  Rybelss (semaglutide) is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.
  Rybelss is usually given after other diabetes medicines have been tried without success.

  The FDA approved once-weekly semaglutide injection for chronic weight management in adults with obesity or with overweight and at least one weight-related condition, according to an agency press release.

  Weekly semaglutide 2.4 mg (Wegoy, Novo Nordisk), a GLP-1 receptor agonist, is the first-approved drug for chronic weight management in adults with general obesity or overweight since 2014. Semaglutide is indicated for chronic weight management in adults with a BMI of 27 kg/m² or greater who have at least one weight-related comorbidity, such as type 2 diabetes or hypertension, or in adults with a BMI of at least 30 kg/m²

  Semaglutide 1 mg injection (Ozempc) was first approved as a treatment for type 2 diabetes in 2017.

  Safety and efficacy of semaglutide 2.4 mg was assessed in four 68-week trials. Three were randomized, double-blind, placebo-controlled trials, including 16 weeks of dose increases, and one was a double-blind, placebo-controlled, randomized withdrawal trial in which patients assigned semaglutide either continued treatment or switched to a placebo
  
  Semaglutide 2.4 mg should not be used in combination with other semaglutide-containing products, other GLP-1 receptor agonists or other products intended for weight loss, including prescription drugs, over-the-counter drugs and herbal products, according to the release. Semaglutide 2.4 mg has not been studied in patients with a history of pancreatitis.
  
  This is a once-weekly injectable, which is more tolerable way of managing obesity vs. other treatments. The STEP study data showed semaglutide 2.4 mg crosses the magic threshold of 10% weight loss for many people who received it. This is another tool that will allow clinicians to better manage obesity.
  
  
  
  
  Function
• Diabetes Type 2 Medicine
• Oral GLP-1RA Medication
• Weight Loss
• Diabetes Mellitus
• Obesity
• Diabetic Coma (in DM Type II)
• Diabetic Ketoacidosis (in DM Type II)
• Cardiovascular Risk Reduction

 

 

 

 

Q1: What's your MOQ?
A:It depends on different products,we can accept sample order or provide free sample for your test.

Q2:How about delivery leadtime?
A:Delivery lead time: About 3-5 days after payment confirmed. (Chinese holiday not included)

Q3: Is there a discount?
A:Different quantity has different discount.

Q4:How to start orders or make payments?
A:Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T, Western Union or Bitcoin.

Q5: How do you treat quality complaint?
A:First of all, our quality control will reduce the quality problem to near zero. If there is a real quality problem caused by us, we will send you free goods for replacement or refund your loss.

Q6. We don't know you at all, how can we trust you?
A: You are always warm welcomed to visit us at any time.Before we start B2B, MIC has audited our company on-spot and approved our credit.Commitment is the No.1 Point of our Enterprise's Value.

Q7.Do you test all your goods before delivery?
A:Yes, we have 100% test before delivery,International Authorized Third-Party Test for the products if you need are highly welcomed.